Stryker is expected to report Q2 2026 revenue of $6.56 billion and earnings of $3.46 per share, with the stock currently trading at $345.08 against an average analyst price target of $393.39.
The primary focus for investors is the company’s recovery from a significant cyberattack in March 2026 that disrupted first-quarter shipments and operations. This quarterly result will serve as a crucial test to see if deferred revenue from that disruption is successfully materializing as projected.
Additionally, analysts are watching for continued momentum in the Orthopaedics segment following the recent U.S. launch of the Mako RPS handheld robotic system.